



# In the SPOTLight

Cancer Science Institute  
of Singapore

[www.csi.nus.edu.sg](http://www.csi.nus.edu.sg)

Issue 2 | February 2014

## A new oncogene that predicts breast cancer response to anti-estrogenic therapies

In a large international collaborative effort, Prof Peter Lobie and colleagues identify a new secreted oncogene that can predict patient response to anti-estrogen therapies.


**11 February 2014**



## An emerging role of PARK2 in cancer

Understand how PARK2 is becoming increasingly important as a pro-survival biological function and tumour suppressor.

**30 January 2014**



## LAMC2 revealed to be potential therapeutic target of anaplastic thyroid carcinoma

Novel study led by Prof H. Phillip Koeffler and Dr Manoj Garg first to demonstrate the effect of laminin-5 gamma-2 on cells affected by this aggressive and untreatable type of cancer.


**23 January 2014**



## New biomarker discovery to improve diagnosis, prognosis and treatment of ESCC

Poor prognosis for patients of Esophageal Squamous Cell Carcinoma (ESCC) may now be a thing of the past as Dr Polly Chen and team identifies ADAR1 as a useful biomarker in detecting ESCC disorders.

**8 January 2014**



## More News

## Save The Date



### CSI brings Christmas joy to patients at Ren Ci Hospital

More than \$5000 was raised and donated to patients in the festive season of giving.

**28 December 2013**



### 2014 Highlights of ASH in Asia

Listen to hematology experts discuss top clinical and translational research at the Highlights of ASH 2014, March 29-30. Registration is now open!